Vanda Pharmaceuticals’ tradipitant shows positive results in nausea, vomiting

Vanda Pharmaceuticals (VNDA) announced positive topline results from its clinical study evaluating tradipitant, an oral neurokinin-1 or NK-1 receptor antagonist, for the prevention of nausea and vomiting induced by GLP-1 receptor agonist Wegovy in overweight and obese adults. This study, which pre-treated patients with either tradipitant or placebo before administering a 1 mg injection of Wegovy, succeeded and met its primary endpoint, with only 29.3% of tradipitant-treated participants – 17/58 – experiencing vomiting compared to 58.6% on placebo, representing a 50% relative reduction. The study also met the key secondary endpoint of the proportion of participants with vomiting and significant nausea at 22.4% in the tradipitant group versus 48.3% on placebo. Tradipitant demonstrated a favorable safety profile consistent with previous studies with no new safety signals observed. The observed efficacy is consistent with tradipitant’s demonstrated performance in motion sickness in multiple studies. Vanda will evaluate an efficient development path towards obtaining regulatory approval for this unmet need. A Phase III program is anticipated to initiate in the first half of 2026, positioning tradipitant as a key adjunct to improve outcomes in GLP-1 agonist treatments.